ArticleBioresources and bioprocessing2021
High-level de novo biosynthesis of glycosylated zeaxanthin and astaxanthin in Escherichia coli.
Article in Bioresources and bioprocessing, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 33 citations in OpenAlex.
- Heterologous Production of 2,2'-Dihydroxy Derivatives of Astaxanthin and Adonirubin inAntioxidants (Basel, Switzerland) · 2026Article
- Harnessing synthetic biology for tetraterpenoid astaxanthin production: Recent advances and challenges.Synthetic and systems biotechnology · 2026Review
- Water-soluble carotenoid: focused on natural carotenoid crocin.Food science and biotechnology · 2025Review
- Biosynthetic Pathway of psi, psi-Carotene fromFrontiers in microbiology · 2025Article
- Enhancing astaxanthin biosynthesis and pathway expansion towards glycosylated C40 carotenoids by Corynebacterium glutamicum.Scientific reports · 2024Article
- Sustainable production of bacterioruberin carotenoid and its derivatives from Arthrobacter agilis NP20 on whey-based medium: optimization and product characterization.Bioresources and bioprocessing · 2023Article
- Gas chromatography - Mass spectrometry (GC-MS) profiling reveals newly described bioactive compounds inHeliyon · 2023Article
- Exploring linker's sequence diversity to fuse carotene cyclase and hydroxylase for zeaxanthin biosynthesis.Metabolic engineering communications · 2023Article
- Metabolic Engineering of Model Microorganisms for the Production of Xanthophyll.Microorganisms · 2023Review
- Optimization of microbial cell factories for astaxanthin production: Biosynthesis and regulations, engineering strategies and fermentation optimization strategies.Synthetic and systems biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
Because of wide applications in food, feed, pharmaceutical and cosmetic industries, the carotenoid market is growing rapidly. Most carotenoids are hydrophobic, which limits their bioavailability. Glycosylation is a natural route that substantially increases the water solubility, as well as the bioavailability, photostability and biological activities of carotenoids. Here, we report metabolic engineering efforts (e.g., promoter and RBS engineering, optimization of carbon sources and supplementation of bottleneck genes) to produce glycosylated carotenoids in Escherichia coli. By fine-tuning the carotenoid-biosynthetic genes (crtX, crtZ and crtY), our strain produced up to 47.2 mg/L (~ 11,670 ppm) of zeaxanthin glucosides, ~ 78% of the total carotenoids produced. In another construct with mevalonate, astaxanthin pathway and crtX genes, the strain produced a mixture of carotenoid glucosides including astaxanthin and adonixanthin glucosides with a total yield of 8.1 mg/L (1774 ppm). Our work demonstrated a proof-of-concept study for the microbial biosynthesis of glycosylated carotenoids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.